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ABSTRACT
Background: Tuberculosis (TB) is a bacterial disease caused by Mycobacterium tuberculosis,
resulting in an estimated one million new cases and over 200,000 deaths annually among children.
TB is the leading cause of death in HIV-infected children globally (Swaminathan & Rekha, 2010),
but few studies have evaluated cofactors of pediatric TB mortality the era ART. We evaluated
predictors of TB mortality in a cohort of HIV-infected hospitalized Kenyan children initiating
antiretroviral therapy (ART).
Methods: HIV-infected children age <12 years were enrolled in four Kenyan hospitals in the
Pediatric Urgent Start of HAART (PUSH) trial. Children were ART-naïve and started ART within
2 weeks of enrollment. All children underwent intensified TB case finding at enrollment and were
evaluated for TB with symptom screening, physical exam and microbiologic evaluation (two
sputum or gastric aspirate samples for AFB, Xpert and culture and one stool Xpert). Children with
suspected tuberculosis were treated by hospital clinicians according to Kenyan Ministry of Health
guidelines and were followed for six months. We evaluated cofactors of mortality using KaplanMeier curves and univariate and multivariate Cox proportional hazard models.
Results: Of 181 ART-naive children enrolled in the study, 14 (8%) had confirmed TB, 81 (45%)
had unconfirmed TB, and 86 (47%) had unlikely TB). Overall, mortality was higher among
children with confirmed TB compared children with Unlikely TB [HR 3.9, 95% CI 1.50 – 9.97).
In multivariate analysis of children with confirmed and unconfirmed TB, higher mortality was
observed among participants without anti-TB treatment (aHR 6.5; 95% CI 2.24–18.84; p<0.001),
orphans and vulnerable children (OVC) (aHR 4.0; 1.41–11.30; p= 0.009), and children with
elevated monocyte-to-lymphocyte ratio >0.378 (aHR 4·5; 1.50 - 13.81; p=0.008).
Conclusion: We observed high mortality among hospitalized HIV-infected children with
confirmed TB. Lack of anti-tuberculosis treatment, high monocyte-to-lymphocyte ratio, and OVC
status were significant predictors of TB mortality. Earlier identification and treatment of TB/HIV
co-infection is urgently needed.
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INTRODUCTION
1.1 Background
Tuberculosis (TB) is a bacterial disease caused by Mycobacterium tuberculosis infecting
approximately two billion people, resulting in approximately 1 million annual cases among
children (Lawn & Zumla, 2011; WHO, 2018c). TB is a leading cause of death in HIV-infected
children globally (Swaminathan & Rekha, 2010). Children more often have more severe forms of
disease such as disseminated TB and TB meningitis (CDC, 2014) and high mortality due to
immature immunological responses to contain the disease. Diagnosing and confirming TB in
children with a laboratory test can be arduous because it is challenging to collect sputum specimens
from young children and infants. Additionally, a smaller number of bacteria (paucibacillary
disease) is required to cause TB disease in children, which results in low sensitivity of
microbiologic testing (Marais, Gie, Hesseling, Obihara, & Nelson, 2004). We studied TBmortality and its determinants among hospitalized antiretroviral treatment (ART)-naive HIVinfected children in Kenya.
REVIEW OF THE LITERATURE
Epidemiology of TB in Children
TB disease ranks among the top 10 causes of death globally, and is the leading cause of a single
infectious agent (Mycobacterium tuberculosis (Mtb)), ranking above HIV/AIDS (WHO, 2018a).
In 2018, 1.1 million children contracted TB disease globally, and 205 000 child deaths were
reported due to TB (including HIV coinfected children) (WHO, 2018b). Pediatric and adolescent
TB is challenging to diagnose and many cases are undetected and not treated (Kibel & Hussey,
1990). Children under five years are at higher risk of developing clinical TB after Mtb infection
and are more likely to develop severe forms of tuberculosis such as tuberculosis meningitis and
disseminated tuberculosis (CDC, 2014). Approximately 50% of cases of pediatric TB occur in
children less than 5 years old (WHO, 2017). However, studies have shown that the rate of TB
progression is highly variable, with the youngest children largely those aged less than two years’
experience the greatest

risk of severe disease and death (Atalell, Birhan Tebeje, &

Ekubagewargies, 2018; Drobac et al., 2012; Jenkins et al., 2017; Marcy et al., 2018).
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Burden of TB in Kenya
The true burden of TB in Kenya has not been consistently monitored; the last TB prevalence survey
prior to 2015 was conducted six decades ago before independence (MOH & NTLP, 2016). In 2015,
the estimated prevalence of all forms of TB for all ages was 426 cases per 100,000 population
while the prevalence of bacteriologically confirmed pulmonary TB in the adult population of
Kenya was 558 cases per 100,000 population (MOH & NTLP, 2016). A total of 81,518 cases were
notified with 83% pulmonary TB cases, of which 45% (36,817) were bacteriologically confirmed.
Of notified TB cases, 8.5% were children aged 0 to 14 years (MOH & NTLP, 2016). The 2015
Kenya tuberculosis prevalence survey did not collect data on children below 14 years and the true
burden of TB in children may be higher than the estimates of 2016 by the center of health solutions.
Epidemiology of TB/HIV in Kenya
Kenya is categorized by the WHO as a high TB and high TB/HIV burden country (WHO, 2018c).
TB disease is the fourth leading cause of death among infectious diseases in Kenya and it is
estimated that about thirty-six percent of TB cases remain undetected and untreated (CHSK,
2017). The TB/HIV co-infection rate has been declining over the years from 60% in 2004 to 31%
in 2015, while the uptake of antiretroviral therapy among HIV co-infected TB patients has been
increasing over time with an uptake of 94% in 2015 (MOH & NTLP, 2016). The primary factor
responsible for the enormous TB disease burden in Kenya is the concurrent HIV epidemic. Kenya
has an estimated 13,000 new pediatric HIV infections that occur annually (NASCOP, 2014),
accounting for 4% of all new pediatric HIV infections globally and 7% of all child deaths
(UNAIDS, 2012). The cumulative incidence for HIV/TB was 40,000 among the 51 million
population and Incidence rate was 79 cases per 100,000 person years in 2018 (WHO, 2018b).
TB/HIV Mortality in Kenya
According to the World Health Organization, over 95% of tuberculosis-related deaths occur in
Less Economically Developed Countries (WHO, 2011) and Kenya is one of those countries. In
2018, cumulative mortality as a result of TB/HIV co-infection was 13,000 cases among the
country’s 51 million population; mortality rate was 26 cases per 100,000 person years (WHO,
2018b). There is lack of data on epidemiology of TB mortality in children posing a challenge in
estimating and comparing incidence and prevalence of TB/HIV mortality in the adult population.
However, the high TB/HIV prevalence among Kenyan adults (Enos et al., 2018) puts children at
risk of acquiring and dying of the disease.
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Kenya has relied on estimates from WHO to extrapolate incidence and case detection rate of TB
(MOH & NTLP, 2016). Risk factors for mortality among children on TB treatment in Kenya have
not been well-characterized and few studies have evaluated TB/HIV in children in the context of
ART. This study sought to evaluate cofactors of TB mortality in a cohort of HIV-infected
hospitalized Kenyan children initiating ART initiation.
Cofactors of TB/HIV mortality in Children
a. HIV and Immunosuppression
HIV infection is known to weaken the immune system, increasing the risk and severity of TB in
HIV patients (Marais, Gie, Schaaf, et al., 2004).The increased risk of mortality among HIVinfected children being treated for TB has been demonstrated in several studies , with a study from
South Africa reporting that TB/HIV co-infected children were approximately seven times more
likely to die than HIV-negative children (Osman et al., 2017). Another study from South Africa
among infants aged 0-12 months excluding infants with unknown HIV status showed that the
relative incidence of pulmonary tuberculosis was 37.8-fold higher among HIV-infected infants,
and the relative incidence of disseminated tuberculosis was 23-fold higher among HIV-infected
infants (Hesseling et al., 2009). Studies have shown that the degree of immunodeficiency in
TB/HIV coinfected children is highly correlated with mortality (Chintu & Mwaba, 2005). HIVInfected children at WHO HIV stage three or four presenting with severe immunosuppression in
Malawi had a higher risk of death than those on Stages one or two (Buck et al., 2013). While
specific mechanisms explaining the vulnerability of HIV infected patients to TB disease are not
yet fully understood, the risk of active TB rises correlates with depletion of CD4 T-cells. HIVinfected patients in high TB incidence areas have a higher risk of developing TB disease after HIV
seroconversion in their first year (Sonnenberg et al., 2005). Low CD4 cell counts are associated
with a higher occurrence of extrapulmonary TB, positive mycobacterial blood cultures, and
atypical chest radiographic findings, reflecting the inability of the impaired immune response to
manage the infection. The crucial role of CD4 T cells in the production of granulomas, and the
depletion of such cells with HIV disease progression, may explain the high risk of extra-pulmonary
TB (EPTB) and mortality in HIV-positive patients (Naing, Mak, Maung, Wong, & Kassim, 2013).
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b. The role of ART
Early initiation of ART reduces mortality risk in HIV-positive patients co-infected with
tuberculosis and is therefore recommended, irrespective of CD4 count (WHO, 2013). The aim of
ART is to achieve long-term viral load suppression assessed with regular viral load measurements.
To the contrary, delayed ART initiation among patients with TB has been shown to be associated
with high mortality. TB/HIV co-infected children in Malawi who had never begun ART treatment
had a more than three-fold higher likelihood of death compared to those already on ART (Buck et
al., 2013). ART, by lowering a person’s viral load and restoring the immune system, significantly
reduces HIV transmission and TB acquisition. Evidence from two randomized controlled trials
and several observational studies in a systematic review and metanalysis showed that initiating
ART at CD4 counts ≤ 350 cells/mm3 significantly reduces mortality, disease progression and the
incidence of opportunistic infections, especially TB (Anglemyer et al., 2014). Although access to
ART has significantly increased in both developed and developing countries, many patients are
still initiating ART late after significant immunosuppression has already occurred.
c. Age
Age is a significant TB risk factor in various biological and social ways. It shapes social status,
social relations, and these behavior aspects are critical in the epidemiology of TB which conforms
to population age structure as countries experience demographic shifts (Toru Mori & Chiu, 2010).
Several studies have shown that children under the age of five years are at higher risk of developing
clinical TB after infection and are more likely to develop severe forms of TB such as TB meningitis
and disseminated TB (CDC, 2014; Nelson & Wells, 2004) especially if not protected by Bacillus
Calmette-Guérin (BCG) vaccination (Marais, Gie, Hesseling, et al., 2004). Younger age (<2 years)
has been associated with over 5-fold increased risk of mortality in HIV-infected children (Marcy
et al., 2018). Individuals in different age strata shape the transmission patterns of TB and inform
potential implications for the design of age-focused epidemiological interventions.
d. Poverty
Tuberculosis has historically been associated with high levels of poverty and its transmission is
enhanced by poor living condition (Bhunu, Mushayabasa, & Smith, 2012). Poverty-stricken people
lack food, stable income, access to healthcare, water and sanitation (WHO, 2005). Extreme poverty
is predominant among certain subgroups of the population and may be associated with other
political and social issues. Vulnerability can emerge from several fronts, including exclusion from
access to opportunities and services as a result of education, income, race, gender, ethnic religious
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affiliation or underlying help-seeking behavior common among orphans and vulnerable children.
UNICEF found out that as of 2015, 13.4 million children and adolescents aged 0 - 17 years in the
world had lost one or both parents due to AIDS and at least 80% (10.9 million) of these children
live in sub-Saharan Africa (UNICEF 2016). Kenya is one of the sub-Saharan countries facing this
significant socio-economic challenge, with 46% of its citizens living below the poverty line
(UNICEF 2016) without proper housing and a considerable proportion living in slums and
informal settlements. A study in Nigeria found that children living in high-density areas and slum
settlements are at high risk for getting TB with nearly half-million new cases are reported each
new year (Morrison, Pai, & Hopewell, 2008). Like any other privileged children, orphans and
vulnerable children require care and support. However, many families struggle to finance health
services. Several studies found that orphaned and vulnerable children lived disproportionately in
the poorest households and are more likely to be underweight (Lindblade, Odhiambo, Rosen, &
DeCock, 2003; Watts et al., 2007).
e. Nutrition
Malnutrition and TB occur at higher frequency in low- and middle-income countries and have a
synergistic relationship affecting child mortality. According to the WHO, these countries account
for 95% of malnutrition cases and deaths from tuberculosis (WHO, 2018b). WHO also states that
malnutrition is an important risk factor for childhood tuberculosis although there are limited
studies to explain the association (WHO, 2006) in part because of the difficult in diagnosing
pediatric tuberculosis and the challenge in establishing a causal role of malnutrition on tuberculosis
(Jaganath & Mupere, 2012). However, children who are malnourished are more likely to acquire
TB and have poor TB outcomes based on available research
f. Disease Severity
Clinical and laboratory markers that indicate higher bacterial burden have been associated with
TB mortality. Radiologically severe TB can be defined as evidence of complications resulting from
typical radiologic manifestations of TB (including cavities, nodal airway obstruction, expansile
pneumonia), or bilateral parenchymal involvement, or overall parenchymal involvement more
extensive than the total area of the right upper lobe, and or disseminated (miliary) TB (Walters et
al., 2017; Wiseman et al., 2012). An increased risk of mortality was seen among children with
miliary TB on chest X-ray (Marcy et al., 2018). Despite major developments in diagnostic
methods in the past years with the invention of automated molecular assays, TB treatment
response is still evaluated using conventional microbiological techniques such as smear
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microscopy and sputum culture. Time to culture positivity can be used as a measure of bacterial
burden and disease severity (Bark et al., 2011). Smear microscopy has been shown to reflect the
extent of disease progression, with greater smear grades being associated with the presence of
cavitary lesions as well as a more extensive lung involvement (Ralph et al., 2010).
g. Monocyte to Lymphocyte ratio
Monocytes cells are considered as the target cells of Mycobacterium tuberculosis, while
lymphocytes are the central effector cells of TB immunity (Naranbhai et al., 2015). Elevated
monocyte-to-lymphocyte ratio has been identified as a risk factor in the development of TB disease
in HIV co-infected children (Sibley et al., 2019) and has been associated with diagnosis of several
diseases; including Hepatitis B (Zhang et al., 2015), HIV (Naranbhai et al., 2014) and tuberculosis
(Naranbhai et al., 2014). Elevated monocyte lymphocyte ratio is associated with active TB and
may reflect bacterial burden in adults; among HIV-infected children a monocyte-to-lymphocyte
ratio of (> 0.378) was associated with TB diagnosis (Choudhary et al., 2019). The monocyte
lymphocyte ratio could also be an indicator of treatment response, as demonstrated in a cohort of
Chinese adults with tuberculosis (Wang et al., 2015). Of note, monocyte-to-lymphocyte ratio has
not yet been evaluated as a predictor of TB mortality.
h. Anti-tuberculosis treatment
TB treatment aims to kill mycobacteria, rapidly stop transmission, and prevent relapse (WHO,
2006). Currently, treatment of tuberculosis involves multiple antibiotics, guided by antibiotic
susceptibility testing when available. TB treatment in Kenya is provided free of charge at all public
health facilities in Kenya; however, TB continues to be a major health problem and children remain
at an increased risk. A significant number of children with TB seeking services at health facilities
are not diagnosed due to the low index of suspicion by health care workers (CHSK, 2017). Taking
a careful history is essential to explore possible TB exposure, prior TB treatment and to perform
adequate symptom characterization (Marais & Schaaf, 2014) to provide unique insight into events
following primary Mycobacterium tuberculosis infection. According to the CDC, people with
recent TB disease infection are at a higher risk of developing TB disease than those who have
never had the disease. In Nigeria, a study demonstrated that children who had a history of prior
TB treatment of either extra-pulmonary or both extra-pulmonary had a higher risk of death
compared to those with no history of TB treatment (Adamu et al., 2017).
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2.1 Study Aims
There is a lack of data on epidemiology of TB mortality in children in Kenya and few studies have
evaluated TB/HIV in children in the context of ART initiation. Our primary aim is to evaluate
cofactors of TB mortality in a cohort of HIV-infected hospitalized Kenyan children initiating
ART.
METHODOLOGY

3.1 Study population and procedures
We performed a secondary analysis of data from the Pediatric Urgent Start of HAART (PUSH)
randomized clinical trial of delayed (<48 hours) versus urgent (7-14 days) ART initiation among
ART-naïve hospitalized children age <12 years in Kenya from April 2013 – December 2015 (NIH
R01 HD023412). Children with suspected central nervous system infection (meningitis,
encephalitis or other) were excluded from this study. Children underwent intensified TB case
finding and were evaluated for TB with symptom screening, physical exam and microbiologic
evaluation (two sputum or gastric aspirate samples for AFB, Xpert and culture and one stool
Xpert). TB was categorized based on NIH 2015 consensus criteria for confirmed, unconfirmed,
and unlikely TB (Graham et al., 2015). Children with suspected tuberculosis were treated by
hospital clinicians according to Kenyan Ministry of Health guidelines and were followed for six
months. We evaluated cofactors of TB mortality in this cohort. All data received for this analysis
are de-identified and do not contain any HIPPA-protected identifiers.

3.2 Statistical analysis
TB mortality was the main outcome of interest, with time from enrolment used in the survival
analysis. Follow-up was either until death, loss to follow-up, study withdrawal, or the final study
visit at six months, based on which took place first. We described patients' baseline characteristics
between TB classification groups. For all children in the study, we estimated the probability of
survival by Kaplan-Meier survival analysis and used the log-rank test to compare survival across
the three tuberculosis strata as well as ascertain the effect of anti-tuberculosis treatment. We then
restricted our analysis to children with confirmed or unconfirmed TB to determine predictors of
TB-related mortality. We included variables of interest identified previously as predictors of TB
mortality [age, residence classification groups, WAZ, CD4% Log10 HIV-RNA, TB treatment and,
prior TB treatment] as well as exploratory variables (OVC status, elevated monocyte-tolymphocyte ratio >0.378). We entered all variables with a p-value of less than 0.10 into the
7|Page

multivariate model to identify independent correlates of mortality through the stepwise entry
selection of explanatory variables into the model. We considered p-value of less than 0.05 as
significant. All analyses were done with SAS software version 9.3 (SAS (r) Proprietary Software
9.3 (TS1M2) Licensed to GEORGIA STATE UNIVERSITY - SFA T&R, Site 70095374).
RESULTS
181 HIV-infected hospitalized ART naïve children were enrolled in the study between April 2013
and May 2013. Of these, 119 (66%), were underweight, and 125 (69%) were severely
immunocompromised. Overall, 14 (8%) children had confirmed TB, 81 (45%) had unconfirmed
TB and 86 (47%) had unlikely TB. (Table 1). Of the 181, 63 children (35%) started antituberculosis treatment; [11/14 (79%) confirmed, 47/81 (58%) unconfirmed and 5/86 (6%) unlikely
TB. Table 1 highlights the baseline characteristics by TB classification groups against mortality.
There are significant differences among children who died and those who survived based on the
TB classification groups. Significant differences were observed based on Age, WAZ, WHZ, MLR
and, log10 HIV-RNA (p<0.05). Table 2 highlights baseline characteristics by pooled Confirmed
and Unconfirmed TB versus unlikely TB against mortality. Significant differences were observed
among children who died and those who survived based on these comparison groups. The
differences were seen for Age, WAZ,WHZ, MLR and, Log10 HIV-RNA (p<0.05). Median
follow-up was 5.6 (IQR 4.2–5·7) months. Overall 6-month mortality was 39 (22%) and most
deaths occurred in the first 2 months of follow up. Overall survival probability was lowest among
confirmed TB at 50% (7 deaths) compared with unlikely tuberculosis at 76% (21 deaths) and
unconfirmed tuberculosis at 86% (11 deaths). There was a significant difference in survival time
across the three TB classification groups after 6 months of follow up (Log rank p-value = 0.012)
as shown in figure 2. Not receiving anti-tuberculosis treatment was associated with a significantly
increased mortality among children with confirmed and unconfirmed tuberculosis (log-rank p <
0·03) as shown in Figure 3. There were significant differences between children who died and
those who survived among those who did not receive ant-tuberculosis treatment based on various
baseline characteristics including: age, OVC status, Weight-for-age Z-score, Weight-for-height Zscore, malnutrition status, WHO stage 3&4, MLR and log 10 HIV-RNA as shown in Table 3. In
Univariate analysis, confirmed tuberculosis was associated with mortality (table 4). Confirmed
tuberculosis was associated with a four-times increase in the risk of death compared with
unconfirmed tuberculosis (Hazard Ratio 3.90, 95% CI 1.5 – 9.97; p-value 0.005).
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Additional factors associated with increased TB-mortality were OVC status (Hazard Ratio 3.15,
1.22 – 8.13; p-value 0.04); lack of anti-TB treatment (Hazard Ratio 2.70, 95% CI 1.10 – 6.81; pvalue 0.02) and monocyte-to-lymphocyte ratio greater than 0.378 (Hazard Ratio 4.33, 95% CI
1.70 – 11.20; p-value 0.002). The association between confirmed TB and mortality disappeared
after stepwise entry of monocyte to lymphocyte ratio, OVC, and Tuberculosis diagnosis and
treatment variables into the multivariate model. Cofactors independently associated with increased
TB-mortality, therefore, include Orphans and Vulnerable Children (Adjusted Hazard Ratio 4.00,
95% CI 1.41 – 11.30; p-value 0.009), lack of TB treatment (Adjusted Hazard Ratio 6.50, 95% CI
2.24 – 18.84; p-value 0.0006), and monocyte-to-lymphocyte ratio greater than 0.378 (Adjusted
Hazard Ratio 4.54, 95% CI 1.50 – 13.81; p-value 0.008).
DISCUSSION
We found high TB mortality in our cohort of hospitalized HIV-infected children, despite access to
anti-tuberculosis treatment and ART. The overall 6-month mortality among children with
confirmed and unconfirmed TB was 19% (18/95), with corresponding mortality rate of 2.3 per 100
person-years. All reported deaths occurred early, within the first two months of follow-up. Our
findings were similar to a recent Ethiopian study of hospitalized TB/HIV co-infected children on
ART reporting 14.02% mortality and mortality rate of 3.27 cases per 100 child-years (Atalell et
al., 2018). Our cohort shared many similarities to this Ethiopian study, including a high proportion
of children who were immunosuppressed with underlying malnutrition. We observed a lower
mortality compared to a Nigerian cohort of TB/HIV co-infected children who were not on ART,
who reported 42% mortality (5.1 cases per 100 person years) (Adamu et al., 2017). Our lower
mortality may be due to our exclusion of CNS involvement, as the Nigerian cohort included
children with extrapulmonary TB, as well as the effect of ART. To our knowledge, this is the first
study addressing predictors of TB mortality in hospitalized HIV-infected Kenyan children starting
ART.

Mortality was higher in children with confirmed tuberculosis than in those with

unconfirmed and unlikely tuberculosis. Our results were consistent with a study among TB/HIV
co-infected children in Burkina Faso, Cameroon, and Nigeria (Adamu et al., 2017; Marcy et al.,
2018). The high mortality observed in confirmed tuberculosis, even though children had access
to treatment could be as a result of higher bacterial burden and disease severity with greater
bacillary loads (Marcy et al., 2018).
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In HIV-infected children with TB disease, initiation of TB treatment is a priority, but the optimal
timing for the initiation of ART during TB treatment is unknown (WHO, 2010). Treatment
outcomes in children are improved if treatment is initiated promptly and adherence is maintained
until completion. The presentation of TB disease in infants may be more acute, resembling severe
acute pneumonia, and should be suspected when there is poor response to antibiotics. Initiating
anti-tuberculosis treatment without bacteriologic confirmation diagnosis TB may require first
putting children on antibiotics to treat pneumonia and, after that, diagnosing TB only after ruling
other possible diagnoses (Onyango, Yuen, Masini, & Borgdorff, 2018). In this study, the decision
to treat was not done by the study clinicians. The results were shared with the hospital staff for
patients who were confirmed with TB. Most cases who did not receive treatment were too sick and
may have be treated but, in some cases, there was not enough time to treat prior to death. The
failure to treat in time supports the fact that sometimes clinicians do not recognize TB early and
are presented later with cases that are too sick to have good treatment outcomes. We hypothesized
that children initiated on anti-TB treatment had better treatment outcomes because they
experienced a significant bacteriological burden reduction. Clinical features suggestive of
tuberculosis disease that were present at baseline had improved, and there was no new clinical
feature suggestive of tuberculosis. Similarly, tolerability to ART treatment might have reduced the
degree of immunodeficiency building a stronger immune system that may explain the drastic
decrease in mortality after the second month of follow up. Monocyte to lymphocyte ratio
previously has been identified as a risk factor in the development of TB disease in HIV in coinfected children and individuals undergoing treatment (Sibley et al., 2019). The association
between the monocyte-to-lymphocyte ratio and the risk of developing mycobacterial infections
was first seen in rabbits in the 1920s (Cunningham R., Sabin F., Sugiyama S., Kindwall J., & J.,
1925; Sabin F. R., Doan C.A., & S., 1926). They demonstrated that the MLR in peripheral blood
could reflect the magnitude and progress of TB disease in rabbit models. Recently, several
published studies suggest that the elevated MLR may be associated with the risk of active
tuberculosis in infants, and in postpartum women infected with HIV (Naranbhai et al., 2014). A
prior study in this same cohort of HIV-infected children showed that elevated monocyte
lymphocyte ratio above 0.378 was associated with active TB (Choudhary et al., 2019).
Studies have shown that continued replication of the pathogen may result to progression to
pulmonary disease and possible dissemination to extra-pulmonary site.
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Dissemination of this disease results in severe forms of TB disease and death (CDC, 2014). We
hypothesized that elevated monocyte-to-lymphocyte ratio reflected an increased bacteriological
burden, and inadequate immune responses may have resulted in death. Tuberculosis transmission
has been influenced dramatically by poor living conditions, and vulnerability may be a
consequence of multifactorial, including socio-economical, environmental, and biological factors.
Orphans and vulnerable children are part of the many community subpopulations that are most
times disproportionately affected by TB. These groups of children with TB and HIV often
experience severe economic barriers to health care, especially meeting expenses related to
diagnosis and treatment. Several studies found that orphaned and vulnerable children lived unfairly
in the poorest households and are more likely to be underweight (Lindblade et al., 2003; Watts et
al., 2007). All these barriers synergistically aggravate economic challenges and prevent or delay
diagnosis, treatment, and successful outcomes, resulting in increased transmission, morbidity, and
mortality. We hypothesized that poor treatment adherence may result from socio-economic
hardships, which may be essential determinants contributing to low cure rates and high risk of
death among poor and vulnerable groups (Storla, Yimer, & Bjune, 2008) but we haven’t assessed
this association among the OVC in this study. Both poor geographical and financial access to
health services synergistically prevent or delay health-seeking among people with TB, especially
the poorest (Munro et al., 2007; Storla et al., 2008) and OVC and could experience late diagnosis
because of socio-economic challenges.

CONCLUSION
Our study observed high TB mortality among hospitalized HIV-infected children starting ART.
Lack of anti-tuberculosis treatment, high monocyte-to-lymphocyte ratio, and OVC status were
significant predictors of TB mortality. We recommend earlier identification and treatment of
TB/HIV co-infection. Future studies to identify reasons for delays in diagnosis and treatment
initiation are needed, and evidence-based interventions will require the involvement of various
stakeholders including the Ministry of Health of Kenya, policy makers and public health agencies.
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Table 1: Baseline patient characteristics by TB classification for the overall cohort (N=181)

Patients’
Characteristics

Confirmed TB
Median (IQR) or n (%)
Died
Survived p-value
(N=7)
(N=7)

Unconfirmed TB
Median (IQR) or n (%)
Died
Survived p-value
(N=11)
(N=70)

0.65
Age in years

6.60
4.04
(0.60 – 7.71) (1.30 – 6.14)

Residence
Nairobi
Gender
Male

7 (100)

3 (43)

4 (57)

5 (71)

OVC status
Yes

5 (71)

5 (71)

Weight-for-Age Z
score

-4.49
-2.70
(-5.18, -1.26) (-4.14, -1.26)

Weight-for Height
Z score

-3.64
-1.98
(-4.26, -2.61) (-2.31, -1.88)

Height-for-Age Z
score
Malnourished?
Yes

-2.79
-1.79
(-3.80, -2.10) (-2.46, -0.77)

0.05
1.29
2.04
(0.48 – 2.00) (1.22 – 5.07)

0.07*
34 (49)

6 (55)

37 (53)
52 (75)

7 (100)

11.80
(4.00 –25.20)

Severely Immunosuppressed? Yes
Log 10 HIV-RNA

Hemoglobin
(g/dL)
Have Anemia?
Yes

22 (34)

0.45
0.002

0.004

-2.40
(-4.01, -1.35)
0.51*

6 (55)

28 (40)

8 (73)

55 (79)

7 (33)

-0.94
(-2.10, 0.38)
0.14
-2.11
(-3.32, -0.74)
0.22*
12 (18)

0.71*

0.70*
9 (43)

31 (48)

14 (67)

35 (54)

0.44*
10 (91)

51 (74)

0.48

CD4%

9 (43)

0.52

0.53

_

0.56
0.40
(0.40 – 0.67) (0.23 – 0.82)

35 (54)

-2.51
(-3.49, -0.90)

-2.44
-3.04
(-3.62, -1.68) (-4.07, -1.59)

1.00*

MonocyteLymphocyte Ratio

13 (62)

-3.23
-1.86
(-4.19, -2.10) (-2.72, -0.82)

-2.98
(-4.16, -1.56)

0.27*

7 (100)

27 (42)

0.44
-2.96
(-3.58, -2.70)

0.15

5 (71)

0.10
13 (62)

0.57
-3.50
-3.32
(-4.62, -2.70) (-4.27, -2.10)

0.18

6 (86)

2.10
(0.90 – 6.15)

0.07*
5 (45)

0.48

Have Pneumonia?
Yes
WHO HIV
Stage 3 & 4

1.16
(0.49 – 1.65)

0.92

1.00*

4 (57)

0.006

0.85
5 (45)

1.00*

1 (14)

Unlikely TB
Median (IQR) or n (%)
Died
survived p-value
(N=21)
(N=65)

0.30

0.02
0.29
0.21
(0.23 – 0.59) (0.15 – 0.35)

0.002
0.55
(0.24 – 0.65)

0.20
(0.14 – 0.33)

0.61
0.82
0.08
11.00
15.60
13.00
12.00
18.00
(6.00 – 15.00)
(3.60 – 25.63) (8.90 – 19.20)
(7.80 – 18.00) (11.00 – 24.50)
0.56*
1.00*
0.08
4 (57)
6 (86)
8 (73)
51 (74)
17 (81)
39 (60)
0.32
0.17
0.0002
5.52
5.65
5.94
5.59
6.27
5.59
(4.92 – 5.61) (5.37 – 5.75)
(5.51 – 6.51) (5.01 – 6.25)
(5.91 – 6.71) (4.86 – 6.09)
0.11
0.56
0.07
8.80
6.90
8.10
8.90
9.60
8.70
(7.90 – 10.90) (5.30 – 8.90)
(7.90 – 9.20) (7.90 – 10.0)
(7.80 – 10.2) (6.90 – 9.60)
1.00*
0.13*
0.33
2 (29)
2 (29)
3 (27)
7 (10)
5 (24)
23 (35)
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Is TST Negative?
Yes
HAART Initiation
Urgent (< 2 days)

1.00*
6 (100)

6 (86)

4 (57)

3(43)

1.00*
5 (100)

59 (91)

6 (55)

37 (53)

1.00*

*Fisher exact test
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0.21
15 (94)

61 (100)

11 (52)

29 (45)

0.92

Abbreviations: IQR – Interquartile range

0.54

Table 2: Baseline patient characteristics by TB classification for the overall cohort (N=181)
Confirmed TB + Unconfirmed TB
Median (IQR) or n (%)
Died
Survived
p-value
(N=18)
(N=77)

Patient’s
Characteristics

Unlikely TB
Median (IQR) or n (%)
Died
Survived
p-value
(N=21)
(N=65)

0.21
Age in years

1.51
2.05
(0.60 – 3.84) (1.26 – 5.07)

0.006
1.16
(0.49 – 1.65)

2.10
(0.90 – 6.15)

0.15
Residence

Nairobi

12 (67)

37 (48)

Gender

Male

10 (56)

42 (55)

OVC status

Yes

11 (61)

22 (29)

0.10
13 (62)

27 (42)

0.94

0.52
13 (62)

35 (54)

9 (43)

22 (34)

0.01

0.45

0.32
Weight-for-Age Z-score

-3.73
-3.29
(-4.75, -2.70) (-4.29, -1.97)

Weight-for-Height Z-score

-2.61
-2.45
(-3.51, -1.32) (-3.81, -1.15)

0.002
-3.23
-1.86
(-4.19, -2.10) (-2.72, -0.82)

0.89

0.004
-2.51
(-3.49, -0.90)

-0.94
(-2.10, 0.38)

0.14
Height-for-Age Z-score

-2.96
-2.55
(-3.69, -2.40) (-3.71, -1.41)

0.14
-2.40
(-4.01, -1.35)

-2.11
(-3.32, -0.74)

0.84
Malnourished?

Yes

7 (39)

32 (42)

Have Pneumonia?

Yes

14 (78)

60 (78)

0.22*
7 (33)

12 (18)

9 (43)

31 (48)

14 (67)

35 (54)

0.99

0.70*

0.11
WHO HIV

Stage 3 & 4

17 (94)

58 (76)

0.30

0.003
Monocyte-lymphocyte ratio

0.44
0.21
(0.26 – 0.59) (0.15 – 0.36)

CD4% at enrollment

15.10
13.00
(4.00 – 25.20) (8.45 – 19.10)

Severely Immuno-suppressed? Yes

12 (67)

Log 10 HIV VL

5.59
5.59
(5.44 – 6.33) (5.03 – 6.19)

Hemoglobin (g/dl)

8.50
8.80
(7.90 – 9.80) (7.70 – 9.90)

0.002
0.55
(0.24 – 0.65)

0.20
(0.14 – 0.33)

0.76

0.08
12.00
18.00
(7.80 – 18.00) (11.00 – 24.50)

0.55*
57 (75)

0.08
17 (81)

39 (60)

0.54

0.0002
6.27
(5.91 – 6.71)

5.59
(4.86 – 6.09)

9.60
(7.80 – 10.2)

8.70
(6.90 – 9.60)

0.94

0.07

0.13*
Have Anemia?
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Yes

5 (28)

9 (12)

0.33
5 (24)

23 (35)

1.00*
Is TST Negative?
HAART Initiation
Urgent (< 2 days)

Yes

*Fisher exact test
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20 (95)

120 (95)

10 (56)

40 (52)

0.21
15 (94)

61 (100)

11 (52)

29 (45)

0.78

Abbreviations: IQR – Interquartile range

0.54

Table 3: Baseline patient characteristics by Treatment status for the overall cohort (N=181)

Characteristics

TB Treatment
Median (IQR) or n (%)
Died
Survived
p-value
(N=11)
(N=52)

No TB Treatment
Median (IQR) or n (%)
Died
Survived
p-value
(N=28)
(N=85)
0.90

Age in years

2.00
2.10
(1.34 – 7.19) (1.23 – 6.12)

0.002
1.01
2.04
(0.42 – 1.78) (0.90 – 5.10)

0.008
Residence

Nairobi

9 (82)

19 (37)

Gender

Male

5 (45)

26 (50)

7 (64)

20 (39)

0.62
16 (57)

47 (55)

0.78

0.40
18 (64)

53 (58)

13 (46)

24 (28)

0.19
Is the child OVC?

Yes

0.08

0.88
Weight-for-Age Z-score

-3.04
-3.65
(-4.98, -2.12) (-4.67, -2.05)

Weight-for-Height Z-score

-2.65
-3.09
(-3.64, -0.52) (-4.08, 1.51)

Height-for-Age Z-score

-3.13
-2.53
(-4.07, -2.15) (-3.56, -0.95)

Malnourished?

Yes

3 (27)

26 (50)

Have Pneumonia?

Yes

10 (91)

43 (83)

0.001
-3.34
-2.02
(-4.55, -2.13) (-2.88, -1.14)

0.42

0.002
-2.54
(-3.50, 0.98)

-1.02
(-2.27, 0.59)

0.32

0.25
-2.71
-2.24
(-3.76, -1.48) (-3.44, -1.15)

0.17

0.04
11 (39)

17 (20)

13 (46)

45 (53)

0.68*

0.55

0.33*
WHO HIV

Stage 3 & 4

11 (100)

43 (84)

0.09
20 (71)

45 (53)

0.009
Monocyte-lymphocyte ratio

0.56
0.25
(0.29 – 0.68) (0.15 – 0.38)

CD4% at enrollment

10.00
(3.00 –25.00)

Severely Immuno-suppressed? Yes

8 (73)

0.0002
0.44
0.20
(0.23 – 0.62) (0.13 – 0.29)

0.80
12.90
(6.00 – 19.00)

0.29
14.78
16.10
(6.50 – 21.90) (10.00 – 24.00)

0.70*
40 (78)

0.22
21 (75)

53 (62)

0.40
Log 10 HIV VL

5.97
5.71
(5.52 – 6.56) (5.30 – 6.30)

0.001
6.09
5.56
(5.57 – 6.60) (4.75 – 6.05)

0.37
Hemoglobin (g/dl)
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8.90
(7.90 – 11.40)

8.85
(7.95 – 9.75)

0.31
8.85
8.70
(7.85 – 10.00) (6.90 – 9.80)

0.09*
Have Anemia?

Yes

4 (36)

7 (13)

0.55
6 (21)

23 (27)

1.00*
Is TST Negative?

Yes

HAART Initiation
Urgent (< 2 days)

*Fisher exact test
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9 (100)

46 (94)

0.46*
17 (94)

79 (98)

14 (50)

40 (47)

0.48
7 (64)

27 (52)

Abbreviations: IQR – Interquartile range

0.79

Table 4: Factors associated with TB-mortality among ART-Naïve Kenyan children (N = 95)

Patients’ Tuberculosis Status
Confirmed tuberculosis
Unconfirmed tuberculosis
Tuberculosis diagnosis and treatment
Did not receive TB Treatment
Received TB treatment
Prior Pulmonary TB Treatment
Yes
No
Age in years
Less than 5 years
5 to 12 years
Residence
Nairobi
Kisumu
Orphans or Vulnerable Children Status
Yes
No
Weight-for-Age Z-score
Less than
–2SD
Greater or equal to –2SD
Weight-for-Height Z-score
Less than
–2SD
Greater or equal to –2SD
Monocyte-to-Lymphocyte Ratio
Greater than 0.378
Less than or equal to 0.378
Hospitalized due to Malaria
Yes
No
CD4 Percentage
Less or equal to 15%
More than 15%
Log10-HIV-RNA
More than 5-log10
Less or equal to 5-log10
Severely immunocompromised
Yes
No
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Univariate analysis
Hazard ratio (95% CI)

P-value
0.005

3.90 (1.50 – 9.97)
Ref

Multivariate analysis
Hazard ratio (95% CI) P-value
0.17
2.34 (0.70 – 7.91)

0.04
2.70 (1.10 – 6.81)
Ref
1.72 (0.50 – 5.95)
Ref

0.0006

0.40

6.50 (2.24 – 18.84)
Ref
-

0.60

-

0.20

-

-

1.40 (0.45 – 4.14)
Ref
-

1.91 (0.72 – 5.10)
Ref
0.02
3.15 (1.22 – 8.13)
Ref
0.42

0.009
4.00 (1.41 – 11.30)
Ref
-

-

1.67 (0.48 – 5.80)
Ref
0.85
1.10 (0.39 – 3.10)
Ref

-

0.002
4.33 (1.70 – 11.20)
Ref

0.008

0.64

4.54 (1.50 – 13.81)
Ref
-

-

0.56

-

-

0.55

-

-

0.51

-

-

0.62 (0.08 – 4.65)
Ref
1.31 (0.52 – 3.31)
Ref
0.74 (0.28 – 1.97)
Ref
0.72 (0.27 – 1.92)
Ref

Analysis Flow Chart
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Figure 1: Kaplan-Meier survival estimates for the overall antiretroviral therapy-naive cohort
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Figure 2: Kaplan-Meier survival analysis on time to death by TB classification groups

Fig 2: There is a significant difference in survival time across TB classification groups in 6.6
months of follow up (Log rank p-value = 0.012).
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Figure 3: Kaplan-Meier survival analysis on time to death by Anti-TB treatment Status

Fig. 3: Anti-tuberculosis treatment was associated with significantly increased survival in a pooled
cohort of children with either confirmed and or unconfirmed tuberculosis. (log-rank p<0·03).
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APPENDICES
Table 5: Supplementary table on baseline patient characteristics by mortality
Died
(N=39)
Median (IQR) or n (%)
1.29
(0.49 – 2.14)

Survived
(N=142)
Median (IQR) or n (%)
2.05
(1.15 – 5.95)

P-Value

Residence - Nairobi

19 (49)

70 (49)

0.95

Gender -

Male

22 (56)

78 (55)

0.87

OVC

Yes

20 (51)
-3.35
(-4.62, -2.12)
-2.55
(-3.51, 0.90)
-2.80
(-3.82, -1.75)

44 (31)
-2.51
(-3.65, -1.36)
-1.57
(-3.03, -0.20)
-2.32
(-3.42, -1.15)

0.02

15 (38)

43 (30)

0.33

23 (59)

91 (64)

0.56

31 (79)
0.45
(0.24 – 0.65)
12.74
(4.00 – 22.00)

93 (66)
0.21
(0.15 –0.35)
14.90
(9.00 – 22.00)

0.11

29 (74)
6.09
(5.55 – 6.60)
8.90
(7.90 – 10.20)

96 (68)
5.59
(4.96 – 6.14)
8.80
(7.30 – 9.80)

0.001

Patient’s
Characteristics
Age in years

-

Weight-for-Age Z-score
Weight-for-Height Z-score
Height-for-Age Z-score
Malnourished?

- Yes

Have Pneumonia?
WHO HIV

Yes

Stage 3 & 4

MLR at enrollment
CD4% at enrollment
Severely Immuno-suppressed?

Yes

Log 10 HIV VL
Hemoglobin (g/dl)

0.003

0.02
0.09
0.12

<.0001
0.36
0.45

0.22

Have Anemia?

Yes

10 (26)

32 (23)

0.68

Is TST Negative?
HAART Initiation
Urgent < 2 days

Yes

26 (96)

126 (95)

0.73

17 (44)

73 (51)

0.39
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